A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML) (cAMeLot-2)
Last Updated June 13, 2025
Want to learn how to participate in this trial?
75276617AML3001
OVERVIEW
-
Sexes Eligible for Study
all -
Age
years -
Phase
phase 3 -
Sites
Sites -
Status
Not yet recruiting
SUMMARY
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML).
CONDITIONS
- Leukemia, Myeloid, Acute
ELIGIBILITY
Inclusion criteria:
* Be 18 years of age or older at the time of informed consent
* Previously untreated lysine N-methyltransferase 2A gene rearranged (KMT2Ar) or nucleophosmin 1 gene mutated (NPM1m) acute myeloid leukemia (AML) with greater than or equal to (> or =) 10% bone mar
DETAILS
LOCATIONS
Country (1) | City or Province (1) | Status |
Israel | Jerusalem Hadassah University Hospita Ein Kerem |
|
31.76904, 35.21633
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.